Humacyte Net Worth
Humacyte Net Worth Breakdown | HUMAW |
Humacyte Net Worth Analysis
Humacyte's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Humacyte's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Humacyte's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Humacyte's net worth analysis. One common approach is to calculate Humacyte's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Humacyte's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Humacyte's net worth. This approach calculates the present value of Humacyte's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Humacyte's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Humacyte's net worth. This involves comparing Humacyte's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Humacyte's net worth relative to its peers.
Enterprise Value |
|
To determine if Humacyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Humacyte's net worth research are outlined below:
| Humacyte had very high historical volatility over the last 90 days | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: Humacyte Shares Surge 38 percent on FDA Approval of Symvess - MarketWatch |
Project Humacyte's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
When accessing Humacyte's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Humacyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Humacyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Humacyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Humacyte. Check Humacyte's Beneish M Score to see the likelihood of Humacyte's management manipulating its earnings.
Evaluate Humacyte's management efficiency
The company has return on total asset (ROA) of (0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.5081) %, meaning that it generated substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.96 in 2024. At this time, Humacyte's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 46.6 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.82).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.13 | 0.14 | |
| Tangible Book Value Per Share | 0.13 | 0.14 | |
| Enterprise Value Over EBITDA | (2.81) | (2.67) | |
| Price Book Value Ratio | 21.68 | 22.77 | |
| Enterprise Value Multiple | (2.81) | (2.67) | |
| Price Fair Value | 21.68 | 22.77 | |
| Enterprise Value | 271.4 M | 284.9 M |
Evaluating the management effectiveness of Humacyte allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Humacyte Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Quarterly Revenue Growth 2.485 | Return On Equity (8.51) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Humacyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Humacyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Humacyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Niklason Laura E over six months ago Disposition of 2625000 shares by Niklason Laura E of Humacyte at 2.75 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Acquisition by Heather Prichard of 136000 shares of Humacyte subject to Rule 16b-3 | ||
Wallace Max N. over six months ago Disposition of 6564 shares by Wallace Max N. of Humacyte at 1.19 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Disposition of 6564 shares by Heather Prichard of Humacyte subject to Rule 16b-3 |
Humacyte Earnings per Share Projection vs Actual
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| MS MS | Chief Officer | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Kiernan MD | Chief Officer | Profile | |
| Dale Sander | Chief CFO | Profile | |
| William Scheessele | Chief Officer | Profile |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.